ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc (AMLX)

2.88
0.14
(5.11%)
Closed March 27 04:00PM
2.86
-0.02
( -0.69% )
Pre Market: 05:15AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.86
Bid
2.83
Ask
2.85
Volume
239
0.00 Day's Range 0.00
2.67 52 Week Range 31.77
Market Cap
Previous Close
2.88
Open
-
Last Trade Time
04:02:13
Financial Volume
-
VWAP
-
Average Volume (3m)
3,012,184
Shares Outstanding
67,782,139
Dividend Yield
-
PE Ratio
3.96
Earnings Per Share (EPS)
0.73
Revenue
380.79M
Net Profit
49.27M

About Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Amylyx Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AMLX. The last closing price for Amylyx Pharmaceuticals was $2.88. Over the last year, Amylyx Pharmaceuticals shares have traded in a share price range of $ 2.67 to $ 31.77.

Amylyx Pharmaceuticals currently has 67,782,139 shares outstanding. The market capitalization of Amylyx Pharmaceuticals is $195.21 million. Amylyx Pharmaceuticals has a price to earnings ratio (PE ratio) of 3.96.

AMLX Latest News

Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX

Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX PR Newswire NEW YORK, March 26, 2024 NEW YORK, March 26, 2024...

INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINE

INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINE PR Newswire SAN...

The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire NEW YORK, March 22, 2024 NEW YORK, March 22, 2024...

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX PR Newswire NEW YORK, March 19, 2024 NEW YORK...

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

- Dr. Zeiher brings more than 20 years of drug development experience in areas with serious unmet treatment needs at companies including Astellas Pharma, Pfizer, Eli Lilly and Company, and Merck...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLX PR Newswire NEW YORK, March 14, 2024 NEW YORK, March 14, 2024 /PRNewswire/ --ย The...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

    Securities and Exchange Commission Washington, D.C. 20549     Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to §...

Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX PR Newswire NEW...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.17-5.610561056113.033.032.6721923282.79826234CS
4-16.94-85.555555555619.819.94882.6765065584.43507972CS
12-13.3-82.30198019816.1619.94882.6730121847.51254659CS
26-15.76-84.640171858218.6219.94882.67225348610.37979307CS
52-27.57-90.601380216930.4331.772.67165113614.58561816CS
156-18.14-86.3809523812141.92972.67127596319.49128034CS
260-18.14-86.3809523812141.92972.67127596319.49128034CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 16.44
(246.11%)
338.8k
BCGBinah Capital Group Inc
$ 21.50
(126.32%)
87.61k
PIKKidpik Corporation
$ 5.55
(69.72%)
628.04k
SSKNStrata Skin Sciences Inc
$ 0.66
(48.35%)
2
KTRAKintara Therapeutics Inc
$ 0.118
(31.84%)
7.45M
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
10
UGROUrban Gro Inc
$ 1.48
(-18.46%)
393
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
33
SOBRSOBR Safe Inc
$ 0.41
(-18.00%)
1.49k
MVLAMovella Holdings Inc
$ 0.0624
(-17.35%)
9.9k
KTRAKintara Therapeutics Inc
$ 0.1181
(31.96%)
7.47M
AKBAAkebia Therapeutics Inc
$ 2.79
(24.55%)
1.99M
CISSC3is Inc
$ 0.0352
(-7.85%)
1.06M
GMDAGamida Cell Ltd
$ 0.0506
(-14.53%)
1.02M
VERBVerb Technology Company Inc
$ 0.2715
(-3.38%)
630.97k

AMLX Discussion

View Posts
maent maent 2 weeks ago
Seems to be settling in around the $3.15 area. Slowly loading this for a swing.
๐Ÿ‘๏ธ0
jmgreeny jmgreeny 2 weeks ago
All the stock give away in Jan to execs really primed the share holders to buy more.
๐Ÿ‘๏ธ0
maent maent 2 weeks ago
I will be very patient with this one. We await news of drug being pulled from the shelves or there is a very good chance they leave it and just change the label. If they allow it to stay on the market, this runs hard!
๐Ÿ‘๏ธ0
GO4AWILDRIDE GO4AWILDRIDE 2 weeks ago
maent

Nice second day cat bounce.

Looking for a higher plateau in the next few days.

GLTU

GO4AWILDRIDE
๐Ÿ‘๏ธ0
maent maent 2 weeks ago
Nice gap that needs to be filled.
๐Ÿ‘๏ธ0
maent maent 2 weeks ago
Volume is ramping up steadily since noon. Nice SC-13G 4.2 Million shares.
๐Ÿ‘๏ธ0
maent maent 3 weeks ago
I could see this getting back to $7-10 by the end of next week.
👍️ 1
CEO_BC CEO_BC 3 weeks ago
$AMLX

Relyvrio treatment a year costs 159K$ per patient. There are 100K patient in US in need for such drug treatment. We did 110M revenue in last quarter reported at 40K$ drug costs which make it to 3K patientโ€ฆ from a market size of 100K (3% adoption)

The market competition for ALS is way higher than for Wolframe Syndrome.

Wolframe Syndrome has 25K patient market size in US and 25K patient in Europe. Europe has a strong need to a better drug for it. There is a strong potential that we reach quick 500M-1B$ revenue a year in the Wolframe Syndrom drugs Market.

I would assume that the company will share soon a market potential and forecast for the treatment of Wolframe Syndrome.

We were at $12 SP before we sold anything. The potential here is still way higher than $12. The larger strategic investors know this too. Expect that some will increase further holding at this price level.
๐Ÿ‘๏ธ0
CEO_BC CEO_BC 3 weeks ago
$AMLX

- pipeline below
-Book Value Per Share: 6.40
-Total Cash Per Share: 5.48
-Net Cash/Share 5.42
-Next catalyst: AMX0035 - (HELIOS)
Wolfram Syndrome: Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024.Phase 2 data due in 2H 2024.
๐Ÿ‘๏ธ0
realtmg realtmg 3 weeks ago
Took a position
๐Ÿ‘๏ธ0
ErnieBilco ErnieBilco 3 weeks ago
That's music to me ears. It was absolutely destroyed today.
๐Ÿ‘๏ธ0
maent maent 3 weeks ago
I flipped it a few times today. I ended up holding 2600 shares for the weekend. This is too good a company. .73 EPS is not a $3 company.
๐Ÿ‘๏ธ0
DD14 DD14 3 weeks ago
262 employees and 400 million in revenue in 2023, thatโ€™s why Iโ€™m taking advantage on this one drug refusal : )))) they have 5 million in cash and revenues.
๐Ÿ‘๏ธ0
DD14 DD14 3 weeks ago
Iโ€™m loading heavy
๐Ÿ‘๏ธ0
DD14 DD14 3 weeks ago
They have many other products, thatโ€™s why the market cap was 1.3 billion.
๐Ÿ‘๏ธ0
girlfriend girlfriend 3 weeks ago
They failed the phase3 for the Phoenix trial and are now going to huddle to see what the next steps are. That's bad news.

I didn't expect the shares to break down as much as they have but I have been a buyer today in the 2.90's up to 3.30.

Best of luck to all they have a rather clean balance sheet.
๐Ÿ‘๏ธ0
GO4AWILDRIDE GO4AWILDRIDE 3 weeks ago
DD14

I hope you are correct, I read the the news release and did not see anything that would make investors drop this stock as much as they did.
I hope to ride this up back to $15-18 or more.

GLTU

GO4AWILDRIDE
๐Ÿ‘๏ธ0
DD14 DD14 3 weeks ago
Watch out, next Monday this will be over $10
๐Ÿ‘๏ธ0
ErnieBilco ErnieBilco 3 weeks ago
Been nibbling this morning gotta be something if the price targets are maintained in the $30s
๐Ÿ‘๏ธ0
Awl416 Awl416 3 weeks ago
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
๐Ÿ‘๏ธ0
jmgreeny jmgreeny 1 month ago
Well their core business saved the shipped?
๐Ÿ‘๏ธ0
Scarface Scarface 1 month ago
Iโ€™ve been told, PHA signed some sort of agreement with BLUE POPPY last week. I canโ€™t find a ticker for BLUE POPPY. I researched BLUEPOPPY.COM
They are for real. The ticker? for the reverse merger? I smell money
๐Ÿ‘๏ธ0
Scarface Scarface 1 month ago
A guy? Went on twitter last night and challenged a tweet from AMYLYX. Iโ€™m telling you this is a big problem for AMYLYX.
๐Ÿ‘๏ธ0
NASDAQ2020 NASDAQ2020 1 month ago
Have someone with Ihub subscription search for chatter on the subject

Keep an eye on Twitter too
๐Ÿ‘๏ธ0
Scarface Scarface 1 month ago
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.990802/full

This is a fact. Read the attached article to the link above. The company behind it is PHA LLC. They own JiWuLiProducts.com
Holders of all Trademarks Intellectual Property for JiWuLi Products in the United States and the European Union. And as of now the only compounder in the world for this treatment. Now what Amylax doesnโ€™t want anyone to know. Ji Wu Li treatment has better results than Relyvrio. Ji Wu Li treatment costs around $1000.00 per month compared to Relyvrio at $12,000. per month. I know PHA is looking at several tickers to do a reverse merger. That ticker will make people a lot of money! Help me
๐Ÿ‘๏ธ0
Scarface Scarface 1 month ago
Amylyx is worried about a company, PHA LLC, trademark holders and intellectual property holder in the United States and the European Union for the Motor Neuron/ALS/LOU GERIG DISEASE. For the Ji Wu Li treatment, beginning in January started shipping Worldwide along with signing significant supply contracts with Neurologists around the world. I was told they were involved with the National Institute of Health published paper, Dr. Sven Schroder from Hamburg, Germany on how Ji Wu Li treatment has better results than Relyvrio at a max treatment cost of $1000.00 per month compared to $12,000.00 per month for Relyvrio. Hereโ€™s kicker, PHA are looking at several reverse merger targets. If knew the target, thereโ€™s money to be made!
👍️ 1
jmgreeny jmgreeny 2 months ago
I canโ€™t believe nobody has been on this page for a long time


So is AMLX broken or just going thru a reboot? Any ideas or opinions or facts someone can put out there
๐Ÿ‘๏ธ0
jmgreeny jmgreeny 3 months ago
So does anybody have an opinion on this stock itโ€™s been a while since any posying
๐Ÿ‘๏ธ0
jmgreeny jmgreeny 5 months ago
Is this company broken. Or should we just wait. Any suggestions
๐Ÿ‘๏ธ0
jmgreeny jmgreeny 6 months ago
So price of Amlx 23-24 price target 50 by financial analyst. Steady slide lower to 18.

Any news on why
๐Ÿ‘๏ธ0
conix conix 1 year ago
Another viewpoint on the ALS drug

https://www.medpagetoday.com/opinion/second-opinions/101206?xid=nl_secondopinion_2022-10-16&eun=g350924d0r
๐Ÿ‘๏ธ0
MiamiGent MiamiGent 1 year ago
Ya Max, I see it kicking up it hoffs, want'n to go.
I have one share as a bookmark. Look'n to pounce on any dip
Have already banked nicely on this

https://stockcharts.com/h-sc/ui?s=AMLX
๐Ÿ‘๏ธ0
Max77 Max77 1 year ago
Notice the cup and handle formation- super bullish chart pattern
๐Ÿ‘๏ธ0
MiamiGent MiamiGent 1 year ago
.
AMLX Amylyx Pharmaceuticals Receives FDA Approval Of Relyvrio For Treatment Of Amyotrophic Lateral Sclerosis
By Benzinga โ€” 4:38 PM ET 09/29/22
๐Ÿ‘๏ธ0
MiamiGent MiamiGent 1 year ago
AMLX The Motley Fool
Sun, September 25, 2022 at 9:23 AM

AMLX Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29.This biotech is ready for blastoff
It's also in the final stages of preparing to launch the drug in the European Union, pending the green light from regulators, which could come in the first half of 2023.

Since its IPO in early January of this year, its shares are up by nearly 61.6%, and it'll likely rise even higher. Right now, its revenue is negligible, as there hasn't been an earnings report since the approval of its drug in Canada. But next year, analysts estimate on average that it'll bring in around $174 million if AMX0035 launches in the U.S. as planned, and that'll mean the company's top revenue growth rate should accelerate dramatically.

NASDAQ: AMLX
Amylyx Pharmaceuticals, Inc.
Today's Change
(+3.23%) $0.91
Current Price
$29.09
KEY DATA POINTS
Market Cap
$2B
Day's Range
$27.95 - $29.45
52wk Range
$6.51 - $33.41
Volume
515,343
Avg Vol
1,572,472
Gross Margin
-20475.44%
Dividend Yield
N/A

Furthermore, there aren't any other ALS medicines, so Amylyx will have free rein of the global market, and that could power shareholder returns for years. And, as it already has its foot in the door thanks to its approval in Canada, it isn't as risky as other biotech stocks, though it's still not exactly a great pick for investors with a low risk tolerance.
๐Ÿ‘๏ธ0
MiamiGent MiamiGent 2 years ago
MiamiGent

Member Level
Re: None

Friday, September 09, 2022 3:32:12 PM

Post#
622407 of 622435

AMLX I just got in at 29.80
Received recommendation of FDA Independant Advisory Committee yesterday
Up 60+% between yesterday and today.
I'm counting on "the three day rule" and publicity over weekend to send it higher Monday
A drug for ALS where there is little to offer sufferers now
https://stockcharts.com/h-sc/ui?s=AMLX
๐Ÿ‘๏ธ0
sorkin sorkin 2 years ago
Bought $30 puts
๐Ÿ‘๏ธ0
sorkin sorkin 2 years ago
Sold my $30 calls
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
And the run continues :))))))))))))))))))))))0
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Oh, ok. I think it's phenomenal. AMLX
๐Ÿ‘๏ธ0
sorkin sorkin 2 years ago
Will SRPT buy AMLX?
๐Ÿ‘๏ธ0
sorkin sorkin 2 years ago
Hope you are not right
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 years ago
your the man of many gif's


reminds me of someone
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 2 years ago
AMLX: Heck, as for myself, I just deploy my (Proprietary/Patented) 'TIME MACHINE' (See my original Patent Office vid., below); go back to the PREVIOUS trading day; buy a big CHUNK of the stock in question; then brag the following day as to how SMART I am!!

๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 2 years ago
AMLX: Well, a classic SUCKERS-BAIT-MORNING-GAPPER today; but nonetheless, perhaps a Medical History 'HOME RUN' (pun intended) for the treatment of old "LOU GEHRIG's DISEASE". (Was this a WITTY post, or WHAT, Dudes??!!!)





๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 years ago
they usually send me a text first

LOL

have a nice day
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
HOD was $35. Could head back that way without notice!
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 years ago
slow chop&grind form the gap up $35 on down
๐Ÿ‘๏ธ0
subslover subslover 2 years ago
Wow!
๐Ÿ‘๏ธ0
Pt3 Pt3 2 years ago
Please unhalted I need 1st entry
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock